Embodiments of the present invention relate to salt forms of triazolopyrazine derivatives. More specifically, embodiments of the present invention relate to salt forms of triazolopyrazine derivatives having pharmacokinetic and therapeutic effects.
Triazolopyrazine derivatives have been described in U.S. Pat. No. 9,403,831 (which is incorporated by reference in its entirety herein) for use in inhibiting the activity of c-Met kinase, and for treatment hyperproliferative disorders. However, these triazolopyrazine derivatives are described in a free base form rather than a salt form.
A need exists for novel salt forms of triazolopyrazine derivatives having advantageous properties while substantially retaining the pharmacokinetic and therapeutic effects of the free base form.
The disclosure provides novel salt forms of triazolopyrazine derivatives represented by formula (1) with improved solubility, stability, and/or other properties while maintaining substantially similar pharmacokinetic properties of the free base form of the compounds.
In one instance, a salt (mesylate salt) of methanesulfonic acid and a triazolopyrazine derivative of formula (1) is provided.
The disclosure also provides compositions of the mesylate salt and a pharmaceutically acceptable carrier.
The disclosure also provides a method for manufacturing the mesylate salt.
The disclosure also provides a method for inhibiting the activity of c-Met kinase in a subject by administering to a subject in need thereof a therapeutically effective amount of the mesylate salt.
The novel salts inhibit the activity of c-Met tyrosine kinase to be useful as a therapeutic agent of various abnormal proliferative diseases associated with excessive cell proliferation and growth due to the abnormal activity of kinase, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy. The present disclosure describes exemplary pharmaceutical compositions for inhibiting the activity of c-Met tyrosine kinase including novel salts as active ingredients and a pharmaceutical composition for preventing or treating hyper proliferative disorders.
In one aspect, in the mesylate salt the triazolopyrazine derivative of formula (1) is the (S) enantiomer. Preferably the triazolopyrazine derivative of formula (1) is optically pure. In an aspect, the level of optical purity is at least 95%, at least 97%, at least 99%, or essentially 100%.
In an aspect, the mesylate salt has any one salt form of Mes1, Mes2, or Mes3. Preferably the mesylate salt has salt form Mes2. In an aspect, the mesylate salt is physically stable at 20 to 50° C. and 35% to 80% relative humidity (RH) for at least 2 days. In an aspect, the mesylate salt is physically stable up to 24 months at ambient conditions. In an aspect, the mesylate salt has API chemical purity of at least about 95%. Preferably the mesylate salt has API chemical purity of about 100%.
In an aspect, the mesylate salt has a High-Throughput X-Ray Powder Diffraction (HT-XRPD) pattern comprising characteristic peaks at about 15.5 to 16.0 2θ (deg), about 17.5 to 18.0 2θ (deg), and about 21.5 to 22.0 2θ (deg). Preferably, the mesylate salt HT-XRPD pattern has characteristic peaks corresponding substantially to:
In an aspect, a method for manufacturing the mesylate salt is provided, including steps of a) adding a compound of formula (1) to a reactor containing a solvent; (b) stirring the compound and the solvent in the reactor; (c) adding methanesulfonic acid to the solution prepared in (b); and (e) cooling the solution prepared in (c) to obtain a precipitate of the mesylate salt. In an aspect, the solvent may be acetonitrile, acetone, 1,2-dimethoxyethane, n-heptane, isopropyl alcohol, water, or THF. In an aspect, the methanesulfonic acid is added to the solution prepared in (b) in an equivalent ratio of about 1:1.5 to about 1:2.5 with respect to formula (1). Preferably, the equivalent ratio is about 1:1.9 to about 1:2.3 and the solvent comprises acetonitrile. In an aspect, step (b) is performed at about 45 to 55° C. for at least about 1 hour.
In another aspect, a pharmaceutical composition is provided, including the mesylate salt and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be one or more of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. The pharmaceutical composition may include one or more of a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, and a preservative.
In another aspect, a method is provided for inhibiting the activity of c-Met kinase in a subject by administering to a subject in need thereof a therapeutically effective amount of the mesylate salt. In an aspect, the subject is suffering from a hyperproliferative disorder. Examples of the hyperproliferative disorder include lung cancer, gastric cancer, pancreatic cancer, colon cancer, ovarian cancer, renal cell cancer, prostate cancer, or a brain tumor. In an aspect, the method is for treating or preventing such hyperproliferative disorders.
While the present disclosure is described in more detail through the following Examples, the scope of the present disclosure is not intended to be limited thereby.
The compound of formula (1) (“ABN-401”) was provided by Abion. All other chemicals were obtained from Fisher Scientific, Sigma Aldrich or VWR. Chemicals used are at least of research grade. The solvents used for LCMS analysis are of LCMS grade.
The approximate solubility was determined by adding small aliquots of solvent (50 μL up to 1 mL, 100 μL above 1 mL) to the solid starting material until complete dissolution was observed or a maximum volume of 4 mL was reached. Afterwards the solvents were evaporated and obtained solids were analyzed by HT-XRPD. The experimental details and results are reported in Table 1.
A thermal stability study was performed on ABN-401 to investigate the chemical stability of the starting material in solution when exposed to elevated temperatures. Solutions of ABN-401 were prepared in acetone, 1,2-dimethoxyethane, and acetonitrile with a concentration of approximately 0.3 mg/mL. Solutions were left at RT for 1 hour and successively, two aliquots of each solution were taken and heated at 50° C. and 80° C. for one hour. All these solutions were analyzed by LCMS. Additionally, the samples kept at RT were remeasured by LCMS after 24 hours to check the chemical degradation over time. No significant chemical degradation was observed in the samples kept at 50° C. and 80° C. The results are summarized in Table 2.
The screen was started by preparing solutions of ABN-401 in acetone, 1,2-dimethoxyethane, and acetonitrile with a concentration of around 25, 13 and 8 mg/mL, respectively. Counterions were added to the API solutions from aqueous solutions, resulting in API:counterion ratios of 1:1.1, 1:2.1 and 1:3.1. The experiments were subjected to a temperature profile including three heating-cooling cycles between 5-50° C. and aging at 25° C. for 3 days (
Upon completion of the aging time, the solids were separated from the liquid phases, dried under vacuum at 50° C. and analyzed by HT-XRPD. The solutions (from the experiments that did not show solids after the temperature profile) and the mother liquors were left to evaporate at room conditions, and the residual solids were analyzed by HT-XRPD. Subsequently, all the solids were exposed to accelerated aging conditions (AAC) at 40° C./75% RH for 48 hours and re-measured by HT-XRPD to test their physical stability.
The mesylate salt, Mes2, was scaled-up to 0.5-gram scale (Exp. ID SSm71). 500 mg of the free base was dissolved in 23 mL of acetone (concentration=26 mg/mL) at RT. Methanesulfonic acid (1M water solution) was added to reach an API:CI molar ratio of 1:2.1. Precipitation of the salt was observed upon addition of the counterion. The suspension was heated to 50° C. and left to equilibrate with continuous stirring at 50° C. for 8 hours. The salt suspension was cooled down to 25° C. The solids were isolated, dried under deep vacuum (10 mbar at 50° C.) and analyzed by HT- and HR-XRPD, TGA/TGMS, DSC, LCMS, 1H-NMR and DVS.
The camsylate salt, Camp2, was scaled-up at 0.3-gram scale (Exp. ID SSm73). 300 mg of free base was dissolved in 15 mL of ACN (concentration=20 mg/mL) at 50° C. Camphor-10-sulfonic acid (136 mg) was added to reach an API:CI molar ratio of 1:1.1. The counterion dissolved, and the solution was left to equilibrate with continuous stirring at 50° C. for 1 hour. The solution was cooled down to 25° C. and aged for 72 hours. The salt had precipitated during the cooling profile. The solids were isolated, dried under deep vacuum (10 mbar at 50° C.) and analyzed by HT- and HR-XRPD, TGA/TGMS, DSC, LCMS, 1H-NMR and DVS.
Physical stability studies (see Table 3) over a prolonged period of time (up to 2 years) were conducted at defined temperatures and relative humidity values (25° C./60% RH and 40° C./75% RH) on the mesylate (Mes2), camsylate (Camp2), and maleate (Mae2) salts. As a reference, a sample of ABN-401 free base was also included in this stability study. At timepoints of 1, 3, 15 and 24 months, the vials containing the solid were analyzed by XRPD, TGMS and HPLC to determine if changes in the solid form had occurred, to confirm the water/solvent content and if chemical degradation occurred after storage at the different conditions.
HT-XRPD patterns were obtained using the Crystallics T2 high-throughput XRPD set-up. The plates were mounted on a Bruker General Area Detector Diffraction System (GADDS) equipped with a VANTEC-500 gas area detector corrected for intensity and geometric variations. The calibration of the measurement accuracy (peaks position) was performed using NIST SRM1976 standard (Corundum).
Data collection was carried out at room temperature using monochromatic Cu Kα radiation in the 2θ region between 1.5° and 41.5°, which is the most distinctive part of the XRPD pattern. The diffraction pattern of each well was collected in two 20 ranges (1.5°≤2θ≤21.5° for the first frame, and 19.5°≤2θ≤41.5° for the second) with an exposure time of 90 s for each frame. No background subtraction or curve smoothing was applied to the XRPD patterns. The carrier material used during HT-XRPD analysis was transparent to X-rays and contributed only slightly to the background.
The powder data were collected on D8 Advance diffractometer using Cu K 1 radiation (1.54056 Å) with germanium monochromator at Room Temperature. The data were collected from 4 to 45 2 with 0.016 2 steps on solid state LynxEye detector with 22 sec/step speed. The sample was measured in 8 mm long glass capillary with 0.3 mm outer diameter.
Mass loss due to solvent or water loss from the crystals was determined by TGA. Monitoring the sample weight, during heating in a TGA/DSC 3+ STARe system (Mettler-Toledo GmbH, Switzerland), resulted in a weight vs. temperature curve and a heat flow signal. The TGA/DSC 3+ was calibrated for temperature with samples of indium and aluminum. Samples (circa 2 mg) were weighed into 100 μL aluminum crucibles and sealed. The seals were pin-holed, and the crucibles heated in the TGA from 25 to 300° C. at a heating rate of 10° C./min. Dry N2 gas was used for purging.
The gases coming from the TGA samples were analyzed by a mass spectrometer Omnistar GSD 301 T2 (Pfeiffer Vacuum GmbH, Germany). The latter is a quadrupole mass spectrometer, which analyzes masses in the temperature range of 0-200 amu.
The DSC thermograms were recorded with a heat flux DSC3+ STARe system (Mettler—Toledo GmbH, Switzerland). The DSC3+ was calibrated for temperature and enthalpy with a small piece of indium (m.p.=156.6° C.; δHf=28.45 J/g) and zinc (m.p.=419.6° C.; δHf=107.5 J/g). Samples were sealed in standard 40 μL aluminum pans, pin-holed and heated in the DSC from 25 to 300° C., at a heating rate of 10° C./min. Dry N2 gas, at a flow rate of 50 mL/min was used to purge the DSC equipment during measurement.
The 1H-NMR spectra were recorded at RT on a 500 MHz Bruker instrument using standard pulse sequences. The samples were dissolved and analyzed in DMSO-d6. The data were processed with ACD Labs software Spectrus Processor 2016.2.2 (Advanced Chemistry Development Inc., Canada).
Starting material characterization and purity assessment of the novel crystalline forms of the free base:
Assay and Purity Assessment of the Novel Crystalline Salts
Method name: S19061_01.M
Concentration: 0.3 mg/ml
Differences in hygroscopicity (moisture uptake) of the various forms of a solid material provided a measure of their relative stability at increasing relative humidity. Moisture sorption isotherms of small samples were obtained using a DVS-1 system from Surface Measurement Systems (London, UK); this instrument is suitable for use with as little as a few milligrams of sample, with an accuracy of 0.1 μg. The relative humidity was varied during sorption-desorption-sorption (40-95-0-40% RH) at a constant temperature of 25° C., typically with a hold time of 60 minutes per step (10% relative humidity step). At the end of the DVS experiment the sample was measured by XRPD.
The hygroscopicity was classified according to the European Pharmacopoeia Hygroscopicity classification. Water uptake percentage at 25° C./80% RH (24 h) is:
Change in mass <0.2%—Non-hygroscopic
Change in mass >0.2% & <2%—Slightly hygroscopic
Change in mass >2% & <15%—Moderately hygroscopic
Change in mass >15%—Very hygroscopic
Mes1 was obtained from the salt formation experiments performed with methanesulfonic acid with an API:CI molar ratio of 1:1 in all three solvents. Table 24 reports the experimental conditions producing Mes1. The solid selected for further characterization was the salt crystallized from acetone with 1 molar equivalent of methanesulfonic acid (Exp. ID SSm4). Mes1 was physically stable after exposure to AAC (40° C./75% RH) for 2 days (
The TGA/TGMS analysis of Mes1 (
The heat flow signal of the TGA showed a broad endothermic event related to the mass loss and an endothermic event at around 160° C., that could be related to the melting of an anhydrous form. The thermal analysis suggested that Mes1 could be a mix hydrated/solvated crystalline salt.
Mes2 was obtained from the salt formation experiments performed with methanesulfonic acid with API:CI molar ratios of 1:2 in all three crystallization solvents and with ratio 1:3 in ACN. Table 7 reports the experimental conditions producing Mes2. The solid selected for further characterization was the salt crystallized from acetone with two molar equivalents of methanesulfonic acid (Exp. ID SSm5). Mes2 was physically stable after exposure to AAC (40° C./75% RH) for 2 days (
The TGA/TGMS analysis of Mes2 (
The heat flow signal of the TGA showed a broad endothermic event related to the water loss and an endothermic event at around 210° C., that could be related to the melting of an anhydrous form. The thermal analysis suggested that Mes2 could be a di-hydrate salt form of the di-mesylate salt.
The DSC trace of Mes2 (
The chemical purity of Mes2 was assessed by LCMS to 100% (
The 1H-NMR analysis of Mes2 is shown in
Mes3 was obtained from the salt formation experiment crystallized from acetone and 1,2-dimethoxyethane with three molar equivalents of methanesulfonic acid. The solid selected for further characterization was the salt crystallized from acetone with three molar equivalents of methanesulfonic acid (Exp. ID SSm6). Table 26 reports the experimental conditions producing Mes3. Although the crystallinity remained, Mes3 became deliquescent after exposure to AAC (40° C./75% RH) for 2 days (
The TGA/TGMS analysis of Mes3 (
Camp1 was obtained from the salt formation experiments performed with camphor-10-sulfonic acid in acetone and 1,2-dimethoxyethane when an API:CI ratio of 1:1 was applied. Table 9 reports the experimental conditions producing Camp1. The solid selected for further characterization was the salt crystallized from acetone with one molar equivalent of camphor-10-sulfonic acid (Exp. ID SSm14). Camp1 was physically stable upon exposure to AAC (40° C./75% RH) for 2 days (
The TGA/TGMS analysis of Camp1 (
The DSC trace of Camp1 (
The chemical purity of Camp1 was assessed by LCMS to 100% (
The 1H-NMR analysis of Camp1 is shown in
Camp2 was obtained from the salt formation experiment performed with camphor-10-sulfonic acid in ACN and an API:CI ratio of 1:1 (Exp. ID SSm60). Table 10 reports the experimental conditions producing Camp2. Camp2 was physically stable upon exposure to AAC (40° C./75% RH) for 2 days (
The TGA/TGMS analysis of Camp2 (
In the heat flow signal a sharp endothermic event was observed at around 200° C. attributed most likely to the melting of an anhydrous phase of the salt, followed by decomposition.
The DSC trace of Camp2 (
A sample of Camp2 (Exp. ID. SSm60) was dried at 80° C. under vacuum with the aim of isolating a potential anhydrous form melting at 208.9° C. observed in the DSC trace. The solid collected was analyzed by HT-XRPD and TGMS. The solid remained Camp2, containing 1.9% of water (
The chemical purity of Camp2 was assessed by LCMS to 100% (
The 1H-NMR analysis of Camp2 is shown in
The HT- and HR-XRPD analysis confirmed the crystallization of Mes2 in the scale-up experiment (Exp. ID: SSm71) (
The TGA/TGMS analysis of dried Mes2 (
The DSC traces of Mes2 (
The 1H-NMR analysis of Mes2 is shown in
At 80% RH the change in mass was approximately 12.2%. Therefore, the mesylate salt Mes2 could be considered moderately hygroscopic (based on the European Pharmacopeia Hygroscopicity classification). No change in the solid form was observed after the DVS analysis.
The HT- and HR-XRPD analysis confirmed the crystallization of Camp2 in the scale-up experiment (Exp. ID: SSm73) (
The TGA/TGMS analysis of dried Camp2 (
The DSC trace of Camp2 (
The chemical purity of Camp2 was assessed by LCMS to 99.7% (
The 1H-NMR analysis of Camp2 is shown in
The DVS analysis showed a change in mass at 80% RH of 1.4% suggesting that this material is slightly hygroscopic (based on the European Pharmacopeia Hygroscopicity classification).
The TGA traces of the 3-months samples of Form A exposed to 25° C./60% RH and to 40° C./75% RH are shown in
The TGA traces of the 15-months samples of Form A exposed to 25° C./60% RH and to 40° C./75% RH are shown in
The TGA traces of the 24-months samples of Form A exposed to 25° C./60% RH and to 40° C./75% RH are shown in
The chemical purity of Form A after 24 months exposure to 25° C./60% RH (Exp. ID GEN81) and to 40° C./75% RH (Exp. ID GEN76) assessed by LCMS was 87.2% and 90.7%, respectively (
The HT-XRPD analysis confirmed that over time solid form conversions occurred upon exposure of Mes2 to 25° C./60% RH and 40° C./75% RH. The changes happened faster at 40° C./75% RH than at 25° C./60% RH. There were no significant differences in the powder patterns of Mes2 for the sample exposed to 25° C./60% RH for 3 months, however, after 15 months additional diffraction peaks were detected at 15.1 and 16.5° 20. This diffraction peaks could be attributed to other crystalline phase; however, the nature of that phase is unknown. The sample exposed to 40° C./75% RH showed these additional peaks after 3 months. After 15 months all peaks of the XRPD were shifted and therefore, it was designated Mes4, while the additional peaks at 15.1 and 16.5° 2θ were still present. After 24 months the solids exposed to both conditions had converted to a novel form and were designed Mes6.
Results of TGA analysis on samples of Mes2 exposed to 25° C./60% RH and 40° C./75% RH for 1 month are shown in
The water uptake was also confirmed in the 3 months samples. The TGA analyses are shown in
The thermal behavior of the samples after 15 months exposure to the storage conditions were similar as the previous samples, although the mass losses were a little less. The TGA analyses are shown in
After 24 months, Mes2 showed mass losses of about 8.6 and 12.0% after incubation at 25° C./60% RH and 40° C./75% RH, respectively (
The chemical purity of Mes2 after exposure to 25° C./60% RH (Exp. ID GEN66) and 40° C./75% RH (Exp. ID GEN70) for 1 month was assessed by LCMS at 100% (
After 3 months, the chemical purities were 99.6 and 99.5% (area %) for the samples exposed to 25° C./60% RH and 40° C./75% RH, respectively (
After 15 months, the chemical purities were 100% (area %) for the samples exposed to 25° C./60% RH and 40° C./75% RH (
The HT-XRPD analysis confirmed that no solid form conversion occurred upon exposure of Camp2 to 25° C./60% RH up to 24 months. However, at 40° C./75% RH, solid form conversions were observed after 3 months. The new powder pattern could be assigned to the powder pattern of Camp4 (identified previously after a DVS analysis performed on Camp2,
The TGA analyses of the solids of Camp2 exposed to 25° C./60% RH and 40° C./75% RH for 1 month are shown in
The sample of Camp2 incubated at 25° C./60% RH for 3 months showed a similar water content to that recorded after 1-month (
The sample of Camp2 incubated at 25° C./60% RH for 15 months showed a similar water content to that recorded after 1 and 3 months (
The sample of Camp2 incubated at 25° C./60% RH for 24 months showed a mass loss of 1.9%, similar to mass loss measured at previous timepoints (
The chemical purity of Camp2 after exposure to 25° C./60% RH for 1 month (Exp. ID GEN50) upon exposure to 40° C./75% RH for 1 month (Exp. ID GEN54) was assessed by LCMS at 99.8% in both cases (
The chemical purity of Camp2 after 15 months exposure to 25° C./60% RH (Exp. ID GEN52) assessed by LCMS was 99.5% (
The chemical purity of Camp2 after 24 months exposure to 25° C./60% RH (Exp. ID GEN53) assessed by LCMS was 100% (
All technical literature or patents cited herein are incorporated by reference in their entirety in the specific context indicated.
While the present invention has been disclosed with reference to certain embodiments, numerous modifications, alterations, and changes to the described embodiments are possible without departing from the sphere and scope of the present invention, as defined in the appended claims. Accordingly, it is intended that the present invention not be limited to the described embodiments, but that it has the full scope defined by the language of the claims listed below, and equivalents thereof.